population may facilitate the definition of increased ADMA concentrations.
The Framingham Heart Study is one of the largest population-based studies to identify risk predictors for cardiovascular morbidity and mortality. Within the Offspring Cohort of this study, we were able to show that ADMA is a risk predictor for total mortality (10 ) . In this context, we now investigate the distribution of ADMA in a reference sample consisting of nonsmoking Framingham Offspring Cohort participants who were free of overt CVD, hypertension, diabetes, and obesity. These individuals underwent measurements of plasma ADMA using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) assay (11 ) . This LC-MS/MS-based assay was chosen because it has previously demonstrated high accuracy and precision (11, 12 ) , factors that are a prerequisite for the determination of reliable reference limits. In addition, we evaluated the cross-sectional correlates of ADMA concentrations in this large community-based sample.
Materials and Methods

STUDY SAMPLE
The design and selection criteria of the original Framingham Heart Study have been described (13 ) . Of the 3532 participants who attended the sixth examination cycle (1995 through 1998), we excluded 212 participants from the present investigation for the following reasons: 15 had a serum creatinine concentration Ͼ176 mol/l (2.0 mg/dL), 79 had missing ADMA, and 118 had missing covariate data. From eligible participants, we excluded all nonhealthy individuals in a stepwise exclusion procedure (Fig. 1) . After exclusion of 39 outliers [ADMA outliers were defined as values ϽQ1 Ϫ 1.5*IQR or ϾQ3 ϩ 1.5*IQR (IQR, interquartile range), according to Solberg and Lahti (14 ) ], 1126 participants made up the reference sample. The ADMA distribution of the reference population is depicted in Fig. 2 . Alternatively, we used a more relaxed definition of outlier identification to generate a second expanded range reference population (ADMA outliers were defined as values ϽQ1 Ϫ 3*IQR or ϾQ3 ϩ 3*IQR). This expanded range reference population included 1162 participants after exclusion of 3 outliers (see Supplemental Fig. 1 , which accompanies the online version of this article at www.clinchem.org/content/vol55/issue8).
At the sixth examination cycle, all attendees underwent standardized measurements of blood pressure (BP), anthropometry, medical history, physical examination, and assessment of laboratory parameters (15, 16 
BLOOD SAMPLE COLLECTION AND ANALYSIS
At the sixth examination cycle, phlebotomy was performed (typically between 0800 and 0900) on fasting participants, who were supine for approximately 5-10 min. Blood was immediately centrifuged, and plasma/ serum were separated and stored at Ϫ80°C until assayed. Blood lipids were analyzed in the Framingham Heart Study laboratory with automated enzymatic assays. High-sensitivity C-reactive protein (hsCRP) and total homocysteine were measured as described (17, 18 ) .
MEASUREMENT OF PLASMA ADMA CONCENTRATION
We performed mass spectrometric measurement of ADMA using a validated high-throughput LC-MS/MS assay that is commercially available (DLD Diagnostika) as described (11, 12 ) . In brief, proteins were precipitated with methanol using 96-well 0.20-m microfiltration plates precoated with 40 pmol [ 2 H 6 ]ADMA (internal standard). After centrifugation, the microfiltrates were dried, and analytes were converted to their butyl ester derivatives. We performed subsequent analyses using a Chirobiotic T, 20ϫ1.0 mm i.d., microbore guard column (Astec) connected to a Varian 1200L Triple Quadrupole MS (Varian) in the positive electrospray ionization (ESIϩ) mode. The sample run time was 1.6 min with intra-and interassay precision of 3.2% and 4.4%, respectively.
STATISTICAL ANALYSES
We used the SAS statistical program (SAS Institute) for statistical analyses. A 2-sided P value of Ͻ0.05 indicated statistical significance. Data are presented as mean (SD) or mean (SE) unless otherwise indicated.
We calculated reference limits according to the recommendations of the IFCC as described (19, 20 ) . ADMA concentrations were normally distributed in our sample (assessed by histograms and normal prob-ability plots), and we analyzed ADMA as a continuous variable (without transformation) and as categorical variable (quartiles). We constructed multivariable linear regression models with stepwise forward selection (significance criterion for entry into the model, P Ͻ 0.1) of variables using the following candidate covariates: age, sex, BMI, SBP, DBP, total/HDL cholesterol ratio, triglycerides, alcohol consumption, hsCRP, eGFR, and total homocysteine.
Results
The characteristics of our reference sample are displayed in Table 1 . The mean age of the participants was 56 years; 60% were women. Women had lower values for DBP, total/HDL cholesterol ratio, total homocysteine, fasting glucose, SBP, BMI (all P Ͻ 0.001), LDL cholesterol (P Ͻ 0.01), and triglycerides (P Ͻ 0.01). Nonhealthy participants were excluded from the reference population by a stepwise exclusion procedure. *Not eligible for the following reasons: serum creatinine concentration Ͼ176 mmol/L (n ϭ 15), missing ADMA (n ϭ 79), and missing covariate data (n ϭ 118).
mol/L compared with postmenopausal women, 0.53 (0.11) mol/L [mean age 61 (8) years, P Ͻ 0.001]. A correlation between age and ADMA was found in women (unadjusted Pearson r ϭ 0.14, P Ͻ 0.001) as well as in men (r ϭ 0.15, P ϭ 0.0017) (Fig. 3) . Also, a correlation between ADMA and homocysteine existed in the reference sample (unadjusted Pearson r ϭ 0.12, P Ͻ 0.001) (Fig. 4) .
The results of the multivariable regression model are shown in Table 2 . We included all candidate variables in a stepwise selection procedure (cutoff for model entry P Ͻ 0.1) and created a final model. Data for men and women were combined, since ADMA concentrations were similar. In the final regression model, age, total homocysteine, and eGFR were positively associated with ADMA, whereas DBP was inversely related to ADMA. Sex, alcohol intake, SBP, blood lipids, BMI, and hsCRP were not associated with plasma ADMA concentration in our sample. We also calculated stepwise selection and regression procedures forcing sex into the model. These models produced the same set of significant variables (age, homocysteine, eGFR, and DBP) for the final model and also a very similar magnitude of each ␤-coefficient and P value (data not shown). Thus, neither stepwise selection nor inclusion of sex had an impact on the multivariable regression procedure output.
Discussion
Experimental and clinical data suggest that increased ADMA concentrations are associated with greater CVD risk (5-9 ). For individual risk stratification, it is a prerequisite to define reliable reference intervals (21 ).
In the present analysis of a large community-based reference sample, we defined the 95% ADMA reference interval from 0.311-0.732 mol/L (2.5th and 97.5th percentiles) in a reference sample without CVD, diabetes, obesity, smoking, or hypertension. The relatively narrow distribution of ADMA concentration has been observed in other cohorts (22 ) and suggests a tight physiological control of ADMA in vivo, presumably by dimethylarginine dimethylaminohydrolase (DDAH) metabolism of ADMA (23) (24) (25) . ADMA plasma concentrations increase by 0.0017 mol/L for each year increase in age (␤, Table 2), after adjusting for other variables in the model. This is consistent with a similar increase reported in a smaller sample of men (26 ) . This association between age and ADMA was evident in women and men (Fig. 3, unadjusted relations) . In line with this finding, premenopausal women had lower ADMA concentrations than postmenopausal women. This confirms previous reports (27, 28 ) and may reflect the influence of estrogens on ADMA concentrations (29, 30 ) . Estrogens enhance DDAH gene expression by promoter activation (31 ) . When menopausal status is considered as a candidate variable in the stepwise procedure, however, this variable does not meet the P Ͻ 0.1 entry selection criterion. Thus, the most likely explanation for the observed difference in ADMA in pre-and postmenopausal women is the different age in these 2 subgroups. This observation is substantiated by previous data from a smaller cohort where younger women (mean age 31 years) had as much as 23% lower ADMA plasma concentrations compared with older women (mean age 62 years) (27 ) . ADMA was determined from EDTA plasma samples using LC-MS/MS and stable isotope dilution with [ 2 H 6 ]ADMA. a Data are mean (SD) or median (Q3-Q1). eGFR was calculated using the MDRD formula.
The finding of a positive association between plasma ADMA and total homocysteine is consistent with recent clinical and experimental studies (26, 32, 33 ) . In our analyses, we observed an increase of ADMA plasma concentrations of 0.0038 mol/L per 1 mol/L increase of homocysteine (Table 2 ). Homocysteine is known to interact with DDAH activity by modification of enzyme redox status and protein stability (34 ) . Despite this biochemical interaction, clinical studies of homocysteine lowering have noted only minor effects on plasma ADMA concentrations (35 ) . Nevertheless, both substances (homocysteine and ADMA) were found to be associated with intimalmedial thickness in other cohorts (36 -38 ) . This suggests that both biomolecules act hand in hand in impairing endothelial function.
Besides age and total homocysteine, ADMA was influenced by eGFR and DBP in our cohort of healthy individuals (Table 2) . It is well known that ADMA is increased in patients with renal function impairment, as well as in patients with increased blood pressure (39 -41 ) . In contrast to previous reports from various patient populations, renal function was neither impaired nor was blood pressure increased in our refer- Data represent mean (SE). The unadjusted relationship between age and ADMA was significant for both men and women (Pearson r ϭ 0.15 and r ϭ 0.14 in men and women, respectively; P Ͻ 0.002 for both). ence sample. The weak positive association between ADMA plasma concentrations and eGFR may thus point to a physiological regulation mechanism of renal filtration, or it may be a chance finding due to the comparatively narrow range of renal function levels included in our study. In line with this interpretation, the positive association observed between ADMA and eGFR is further weakened for the expanded-range reference population (online Supplemental Tables 1 and  2) . Under pathophysiologic conditions, however, impaired renal excretory function or impaired renal DDAH activity may dominate and explain the inverse associations between ADMA and eGFR found in most previous studies. Also, the unexpected weak negative association between ADMA and DBP in our healthy reference cohort was further weakened when the relation was examined in the expanded-range reference population (online Supplemental Table 1 ) with the stepwise multivariable regression model (online Supplemental Table 2). Again, under pathophysiological conditions, impaired DDAH activity may become predominant. In consequence, ADMA degradation is impaired, ADMA accumulates, and blood pressure increases. This association is clearly evidenced by gene polymorphism studies and genetically modified animal models (23) (24) (25) 42 ) .
STRENGTHS AND LIMITATIONS
The large community-based reference sample and the quantification of ADMA plasma concentrations by a validated LC-MS/MS method are strengths of our investigation. We acknowledge several limitations, however. We evaluated a community-based reference sample of white, middle-aged individuals of European descent. Caution must be exercised in extrapolating these results to other populations of different ethnicity or with a different age range. Also, from our epidemiological data, no functional conclusions of the observed associations can be made.
Conclusions
We have formulated reference limits for plasma ADMA concentrations using a large community-based reference sample. The relatively narrow distribution of ADMA concentration suggests a tight physiological control of ADMA plasma concentrations, presumably by DDAH metabolism of ADMA.
